Abstract | INTRODUCTION:
Psoriasis is a chronic, disabling, inflammatory skin disease whose pathogenesis still remains to be fully elucidated. Genetic and environmental factors induce an immune response mediated by several cytokines and chemokines, including IL-17A. AREAS COVERED: Emerging evidence now suggests that IL-17A is central in the pathogenesis of psoriasis. Three agents neutralizing IL-17 (i.e., secukinumab and ixekizumab) or antagonizing its receptor (i.e., brodalumab) are in development and are being studied in Phase III clinical trials to evaluate their overall efficacy and safety. However, Phase II results of IL-17 blockade with each of these agents has shown a marked improvement of disease severity, thus confirming the pathogenic relevance of IL-17 in mediating crucial inflammatory circuits in psoriasis. EXPERT OPINION:
|
Authors | Andrea Chiricozzi, James G Krueger |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 22
Issue 8
Pg. 993-1005
(Aug 2013)
ISSN: 1744-7658 [Electronic] England |
PMID | 23731078
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Biological Factors
- Interleukin-17
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Biological Factors
(therapeutic use)
- Humans
- Interleukin-17
(antagonists & inhibitors, immunology)
- Psoriasis
(drug therapy, genetics, immunology)
- Transcriptome
|